Phaseline

Companies › Idera Pharmaceuticals

Idera Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tilsotolimod
Toll-like receptor 9 agonist
TLR9Phase 2Solid Tumor; Malignant Melanoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03865082TilsotolimodPhase 2Solid TumorOncologyMar 2022
NCT04126876TilsotolimodPhase 2Malignant MelanomaOncologyNov 2031

Targets

TLR9 (1)

Companies with the same targets

TriSalus Life Sciences

Companies built like this

Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.